ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, has announced that its affiliate, OncoX BioPharma Inc., has acquired full ownership of the Lycopenoid Lycogen® platform from Asia-Pacific Biotech Developing Inc. (APBDI). This acquisition, valued at approximately USD $4.06 million, includes patented manufacturing technology and commercialization rights, marking a significant step in ABVC's strategy to expand its oncology portfolio. The transaction exemplifies ABVC's approach to leveraging affiliate-driven development for non-dilutive revenue growth, a model that has already demonstrated viability through an existing licensing agreement with OncoX valued up to $105 million, which has delivered equity-based consideration internally valued at $25 million.
The Lycogen® platform, known for its next-generation lycopene-analog produced by microbial fermentation, has shown preclinical promise in cancer-related and metabolic disease models. With potent antioxidant and anti-inflammatory properties, the platform is expected to unlock commercial potential across dermatology, oncology, and nutraceutical sectors. OncoX estimates that cumulative revenue from the platform could approach USD $25–30 million over the next five years, with a share of these revenues flowing back to ABVC through royalty payments. This positions the acquisition as a strategic move within growing markets; the global oncology drug market, which exceeded USD $208 billion in 2023, is projected to grow to $484 billion by 2032, while the lycopene-based ingredients market is expected to surpass $170 million by 2029, highlighting demand for multifunctional natural compounds.
Dr. Uttam Patil, ABVC Chief Executive Officer, emphasized the transaction's role in enhancing the company's position in botanical oncology innovation and its ability to convert platform assets into monetizable growth. The acquisition not only strengthens OncoX's commercialization capability but also reflects ABVC's long-term growth architecture through tiered partnerships. For more information on ABVC BioPharma, visit https://www.abvcbiopharma.com. The acquisition underscores a broader industry trend where biopharmaceutical firms are expanding portfolios through strategic acquisitions of natural compound platforms to address the expanding therapeutic and consumer markets, leveraging non-dilutive models to fuel growth without shareholder dilution.
